Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 140.50 GBp
Change Today 0.00 / 0.00%
Volume 12.9K
As of 9:44 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

summit therapeutics plc (SUMM) Snapshot

140.50 GBp
Previous Close
140.50 GBp
Day High
140.50 GBp
Day Low
140.50 GBp
52 Week High
03/2/15 - 185.00 GBp
52 Week Low
12/3/14 - 107.00 GBp
Market Cap
Average Volume 10 Days
-0.26 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

summit therapeutics plc (SUMM) Related Businessweek News

No Related Businessweek News Found

summit therapeutics plc (SUMM) Details

Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company develops SMT C1100, an utrophin modulator that is in Phase Ib clinical study for the treatment of DMD; and SMT 19969, a novel antibiotic, which is in Phase II proof of concept clinical trial for the treatment of CDI. It has strategic alliance with the University of Oxford to develop the future generation utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.

25 Employees
Last Reported Date: 05/7/15
Founded in 2003

summit therapeutics plc (SUMM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.0K GBP
Chief Financial Officer
Total Annual Compensation: 198.5K GBP
Compensation as of Fiscal Year 2015.

summit therapeutics plc (SUMM) Key Developments

Summit Therapeutics plc Presents Additional Data from Phase 1b Modified Diet Clinical Trial of SMT C1100 in DMD Patients

Summit Therapeutics plc presented detailed pharmacokinetic data from the Phase 1b modified diet clinical trial of SMT C1100 for the treatment of DMD, as well as preclinical data supporting both SMT C1100 and the broader utrophin modulator pipeline, at the 20th International Congress of the World Muscle Society. SMT C1100 is a utrophin modulator that the Company believes has potential to treat all patients with DMD. As previously reported, the Phase 1b modified diet trial met its primary objective. In this trial, increases in plasma absorption of SMT C1100 were observed in DMD patients who received SMT C1100 while following specific dietary guidance providing for a balanced diet of fats, proteins and carbohydrates. In the detailed pharmacokinetic data to be presented at WMS, ten of 12 patients achieved plasma exposure levels above 30 ng/ml for a mean of 14 hours in a 22-hour period, and six of those patients achieved plasma exposure levels above 67 ng/ml for a mean of 8.2 hours in the 22-hour period. These plasma levels correlate to an in vitro increase in utrophin levels of approximately 30% and 50%, respectively, in DMD myoblast cells and human myotubes. Since sustaining utrophin production is likely to be key in providing therapeutic benefit, the remaining two patients may also achieve some clinical benefit as they had plasma levels that exceeded 20 ng/ml. Summit's upcoming Phase 2 proof of concept trial will evaluate the potential benefit of SMT C1100 with longer-term dosing. Based on the detailed analysis of the Phase 1b modified diet trial, drug plasma exposure will not be used as an entry criterion for the Phase 2 proof of concept trial. Summit plans to initiate its Phase 2 proof of concept trial of SMT C1100 in patients with DMD in the fourth quarter of this year. The 48-week open-label study is expected to enroll up to 40 patients between the ages of five and 10 years old at sites in Europe and in the US. Planned endpoints are expected to include changes in the fat content of muscle and in muscle inflammation as measured by magnetic resonance imaging of the leg muscles, measurements of utrophin protein and muscle fibre regeneration from muscle biopsies, and functional measures such as the six minute walk test and the North Star Ambulatory Assessment. The company expects to report data from this trial periodically over the course of the study. The design and initiation of this study remain subject to regulatory approval. In addition, Summit continues to evaluate the timing and design for a larger, placebo-controlled trial of SMT C1100.

Summit Therapeutics Presents New Preclinical Data on Novel C. Difficile Antibiotic SMT19969 at ICAAC 2015

Summit announced new preclinical data on SMT19969, a novel and selective oral antibiotic for the treatment of CDI, will be presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy ('ICAAC 2015') being held in San Diego, USA from September 17-21, 2015. The data being presented are from preclinical in vitro studies that provide further evidence to support SMT19969's profile as a potential treatment for CDI and ability to reduce the high rates of recurrence currently associated with the disease. SMT19969 was shown to have high potency against 107 clinical isolates of C. difficile selected to maximise the diversity of their resistance to common classes of antibiotics, and SMT19969 also continues to display a low resistance development profile. The results will be detailed in two poster presentations to be given by Summit's collaborators: Professor Mark Wilcox (Leeds Teaching Hospitals and University of Leeds, UK) and Dr. Joseph Blondeau (Royal University Hospital and the University of Saskatchewan, Canada). The details of the presentations are as follows: SMT19969 has good activity against prevalent Clostridium difficile ribotypes with varying antimicrobial resistance. J Freeman, J Vernon, R Vickers and M.H. Wilcox (Poster C-618): This study assessed SMT19969 against 107 clinical isolates of C. difficile that had been selected to maximize the diversity of the isolates resistance to key classes of commonly used antibiotics. The results show that SMT19969 was highly active against all C. difficile clinical isolates, displayed superior potency against C. difficile isolates compared to vancomycin and metronidazole, and comparable potency to fidaxomicin. SMT19969 displayed no evidence of cross-resistance with other classes of antibiotics in routine clinical use. Mutant Prevention Concentration values of SMT19969 against Clostridium difficile isolates using a modified microbroth dilution method. J.M. Blondeau, S Shebelski, R. Vickers (Poster D-212): The study evaluated the mutant prevention concentration ('MPC') of SMT19969 to determine the drug concentration threshold that blocks the growth of the least susceptible cells present in bacterial populations. The results show that SMT19969 had low MPC values against clinical isolates of C. difficile and provide further evidence supporting its low resistance development profile.

Summit Therapeutics plc Completes Targeted Enrolment for SMT19969 Phase 2 Trial for C. Difficile Infection

Summit Therapeutics plc announced the completion of patient enrolment into the CoDIFy Phase 2 proof of concept trial of SMT19969 for the treatment of CDI. Patient dosing and follow-up is continuing and top-line results are expected in the fourth quarter of 2015. SMT19969 is a novel, oral antibiotic designed to selectively target C. difficile bacteria while not harming the gut microbiome that is essential in protecting against disease recurrence. SMT19969 has received Qualified Infectious Disease Product designation ('QIDP') and Fast Track status from the US Food and Drug Administration.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUMM:LN 140.50 GBp 0.00

SUMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SUMM.
View Industry Companies

Industry Analysis


Industry Average

Valuation SUMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales NM Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMMIT THERAPEUTICS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at